浙江东亚药业股份有限公司 关于召开 2024 年第二次临时股东大会的通知 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： 一、 召开会议的基本情况 证券代码：605177 证券简称：东亚药业 公告编号：2024-080 债券代码：111015 债券简称：东亚转债 召开的日期时间：2024 年 10 月 11 日 14 点 00 分 股东大会召开日期：2024年10月11日 本次股东大会采用的网络投票系统：上海证券交易所股东大会网络投票 系统 (一) 股东大会类型和届次 2024 年第二次临时股东大会 (二) 股东大会召集人：董事会 (三) 投票方式：本次股东大会所采用的表决方式是现场投票和网络投票相结 合的方式 (四) 现场会议召开的日期、时间和地点 召开地点：浙江省台州市黄岩区劳动北路 118 号总商会大厦 23 层公司会议 室 (五) 网络投票的系统、起止日期和投票时间。 网络投票系统：上海证券交易所股东大会网络投票系统 网络投票起止时间：自 2024 年 10 月 11 日 至 2024 年 10 月 1 ...

附件 2 独立董事候选人声明与承诺 本人冯燕,已充分了解并同意由提名人浙江东亚药业股份有限公 司董事会提名为浙江东亚药业股份有限公司第四届董事会独立董事 候选人。本人公开声明,本人具备独立董事任职资格,保证不存在任 何影响本人担任浙江东亚药业股份有限公司独立董事独立性的关系, 具体声明并承诺如下: 一、本人具备上市公司运作的基本知识,熟悉相关法律、行政法 规、部门规章及其他规范性文件,具有 5 年以上法律、经济、会计、 财务、管理或者其他履行独立董事职责所必需的工作经验。 被提名人已经参加培训并取得证券交易所认可的相关培训证明 材料。 二、本人任职资格符合下列法律、行政法规和部门规章以及公司 规章的要求: (一)《中华人民共和国公司法》关于董事任职资格的规定; (二)《中华人民共和国公务员法》关于公务员兼任职务的规定 (如适用): (五)中共中央组织部《关于进一步规范党政领导干部在企业兼 职 (任职) 问题的意见》的相关规定 (如适用): (六)中共中央纪委、教育部、监察部《关于加强高等学校反腐 倡廉建设的意见》的相关规定（如适用); (七)中国人民银行《股份制商业银行独立董事和外部监事制度 指引》等的相关规 ...

| 证券代码：605177 | 证券简称：东亚药业 | 公告编号：2024-078 | | --- | --- | --- | | 债券代码：111015 | 债券简称：东亚转债 | | 浙江东亚药业股份有限公司 第三届董事会第三十次会议决议公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 一、董事会会议召开情况 浙江东亚药业股份有限公司（以下简称"公司"）第三届董事会第三十次会议于 2024 年 9 月 25 日（星期三）以现场结合通讯的方式召开。本次会议通知于 2024 年 9 月 20 日以邮件的方式发出。本次会议应出席董事 7 人，实际出席董事 7 人。 表决结果：7 票赞成、0 票反对、0 票弃权。 本议案尚需提交公司股东大会审议。 （二）审议通过《关于公司董事会换届选举暨提名第四届董事会独立董事候选 人的议案》 同意提名綦方中先生、崔孙良先生、冯燕女士为公司第四届董事会独立董事候 选人。 具体内容详见公司同日在上海证券交易所网站（www.sse.com.cn）披露的《关于 董事会、监事会换届选举的公告》（公告编 ...

一、对外投资的概述 | 证券代码：605177 | 证券简称：东亚药业 | 公告编号：2024-075 | | --- | --- | --- | | 债券代码：111015 | 债券简称：东亚转债 | | 浙江东亚药业股份有限公司 关于合作设立医药投资基金并共同发起设立 医药开发公司的进展公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 浙江东亚药业股份有限公司（以下简称"公司"或"东亚药业"）系一家从 事原料药及医药中间体的研发、生产与销售的上市公司，利用原料药技术与产能 优势，拓展下游制剂业务，实现向原料药+制剂一体化发展转型。 公司于 2024 年 5 月 20 日召开第三届董事会第二十七次会议、第三届监事会 第二十五次会议，审议通过《关于拟合作设立医药投资基金并共同发起设立医药 开发公司的议案》。公司拟使用自有资金与杭州嘉富天成股权投资管理有限公司、 三门县金融投资有限责任公司、台州市北部湾区经济开发集团有限公司、台州市 海盛产业投资有限公司共同出资设立台州嘉富泽亚股权投资合伙企业（有限合伙） （以下简称"合伙企 ...

| | | 债券代码：111015 债券简称：东亚转债 浙江东亚药业股份有限公司 关于不向下修正"东亚转债"转股价格的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： 自 2024 年 8 月 27 日至 2024 年 9 月 23 日，浙江东亚药业股份公司（以 下简称"公司"）股票在连续三十个交易日中已有十五个交易日收盘价格低于"东 亚转债"当期转股价格的 90%（即 18.25 元/股）的情形，满足《浙江东亚药业股 份有限公司向不特定对象发行可转换公司债券募集说明书》（以下简称"《募集 说明书》"）中规定的转股价格向下修正的条件。 自 2024 年 2 月 23 日至 2024 年 3 月 14 日，公司股票连续十五个交易日收 盘价格低于"东亚转债"当期转股价格的 90%（即 22.46 元/股）的情形，触发 "东亚转债"的转股价格修正条件。为支持公司长期稳健发展，优化公司资本结 构，维护投资者权益，自 2024 年 4 月 3 日起，"东亚转债"转股价格由 24.95 元 /股调整为 20.60 元/ ...

Company Overview - Zhejiang Dongya Pharmaceutical Co., Ltd. was established in 1998 and listed on the Shanghai Stock Exchange on November 25, 2020 [3] - The company specializes in the R&D, production, and sales of chemical raw materials and pharmaceutical intermediates, with a global sales network covering over 50 countries and regions [3] - The company has received multiple accolades, including "National High-tech Enterprise" and "Zhejiang Patent Demonstration Enterprise" [3] Business Strategy - The company aims to enhance its core competitiveness by expanding into generic drugs and innovative drugs while maintaining a focus on raw materials [4] - A long-term strategy is in place to develop a comprehensive health product provider, integrating specialty intermediates, high-end raw materials, and formulations [5] Financial Performance - For the first half of 2024, the company reported a revenue of CNY 648.23 million, a slight decrease of 3.85% year-on-year [4] - The net profit attributable to shareholders was CNY 32.47 million, down 40.54%, with a gross margin of 25.81%, an increase of 1.53% compared to the previous year [4] Market Demand and Trends - The demand for antibiotics remains strong due to factors such as flu outbreaks and the essential nature of antibiotics in healthcare [5] - Macroeconomic stability in China is driving an increase in disposable income and healthcare spending, contributing to a rigid growth in pharmaceutical consumption [5] Future Growth Points - The company has significant market space for its main products, driven by an aging population and increasing health awareness [8] - Ongoing investments in R&D are expected to yield new raw materials, with products like cefoperazone and luliconazole entering production [8] - The establishment of a formulation production base is anticipated to generate additional revenue and boost related raw material sales [8] Operational Insights - The company is currently developing a production base in Jiangxi, which is expected to enhance the variety and scale of production for intermediates and raw materials [6] - Management expenses have increased due to the establishment of new R&D centers and the expansion of production personnel [6] Investor Relations - The company has engaged in various investor relations activities, including analyst meetings and media interviews, to maintain transparency and communication with stakeholders [2]

Group 1: Company Growth Strategies - The company's future performance growth points include new product development, with ongoing investments in raw material drugs like Edaravone [3] - Capacity expansion is underway, with IPO fundraising projects completed in 2023 and production ramping up in 2024 [3] - The company is pursuing international certifications for raw materials to expand into high-end markets in Europe, the U.S., and Japan, as well as mid-to-low-end markets in Central Asia and the Middle East [3] - The completion of convertible bond fundraising projects is expected to significantly boost the growth of new formulation products [3] Group 2: Investment and Market Expansion - The establishment of a pharmaceutical investment fund aims to leverage raw material technology and capacity advantages to expand downstream formulation business [3] - In the first half of 2024, the company actively participated in international exhibitions and strengthened international registrations to enhance overseas market share [3] Group 3: Share Buyback and Financial Performance - As of July 31, 2024, the company completed its share buyback, acquiring 2.170103 million shares, representing 1.8911% of total share capital, with a total investment of 54.99217944 million yuan [3] Group 4: Production Capacity and Utilization - The company is progressing with capacity expansion, with high overall utilization rates and further growth potential as it expands into overseas markets [4] - The production facilities for the formulation segment are nearing completion, with ongoing expansion work for intermediates [4] Group 5: Future Development Strategy - The company plans to focus on raw materials while expanding into material chemistry and intermediates, as well as investing in generic drugs, improved new drugs, innovative drugs, and health products [4] - The goal is to achieve integrated development of specialty intermediates, high-end raw materials, and formulations, positioning the company as a comprehensive provider of health products [4] Group 6: Environmental Initiatives - The introduction of environmentally friendly biocatalytic processes aims to reduce costs and improve efficiency, with high acceptance rates among domestic and international customers [5]

Financial Performance - The company's operating revenue for the first half of 2024 was approximately CNY 648.23 million, a decrease of 3.85% compared to CNY 674.18 million in the same period last year[17]. - The net profit attributable to shareholders for the first half of 2024 was CNY 32.47 million, down 40.54% from CNY 54.61 million in the previous year[17][19]. - The basic earnings per share decreased by 39.58% to CNY 0.29 from CNY 0.48 in the same period last year[18]. - The company's net assets attributable to shareholders at the end of the reporting period were CNY 2.01 billion, a decrease of 0.42% from CNY 2.02 billion at the end of the previous year[17]. - The company reported a net cash flow from operating activities of CNY -122.65 million, indicating a significant cash outflow during the reporting period[17]. - The weighted average return on net assets decreased to 1.61%, down from 2.92% in the previous year, reflecting a decline of 1.31 percentage points[18]. - In the first half of 2024, the company achieved revenue of 648.23 million yuan, a decrease of 3.85% year-on-year, and a net profit of 32.47 million yuan, down 40.54% year-on-year[49]. - The company reported a total comprehensive income for the first half of 2024 of CNY 8,548,084.78, down from CNY 27,456,102.62 in the same period of 2023, indicating a decline of approximately 68.9%[142]. Research and Development - R&D investment in the first half of 2024 reached 52.80 million yuan, an increase of 70.16% year-on-year, accounting for 8.15% of total revenue[49]. - The company has established modern R&D centers in Shanghai and Hangzhou, and has received multiple certifications including CGMP and EDQM for its products[23]. - The company is focused on developing new products, including broad-spectrum antifungal agents and treatments for various infections[26]. - The company is actively transitioning from raw materials to formulations, aiming for integrated production to enhance product value and profitability[47]. - The company has obtained a total of 42 authorized patents, including 34 invention patents, as of June 30, 2024[45]. Market and Sales Strategy - The company has a global sales network covering over 50 countries and regions, with long-term partnerships established in Europe, Southeast Asia, and other areas[23]. - The company primarily utilizes direct sales in the domestic market, leveraging its scale and product quality to maintain customer relationships[30]. - The company has developed a dual sales model for international markets, combining direct sales and distributor partnerships to enhance market reach and efficiency[32]. - The company has formed stable partnerships with several high-market-share formulation enterprises, enhancing its competitive position in the market[41]. - The integration of APIs and formulations is becoming a key trend in the pharmaceutical manufacturing sector, supported by government policies promoting collaboration[38]. Financial Management and Governance - The company has established a profit distribution policy and shareholder dividend return plan, detailing the ratio, basis, conditions, and implementation procedures for dividends[103]. - The company is committed to enhancing investor returns and will publicly explain any failure to fulfill commitments at the shareholders' meeting[103]. - The company has implemented measures to ensure fair pricing in related transactions to protect the interests of the company and its shareholders[101]. - The company has a structured approach to managing related party transactions to avoid conflicts of interest[101]. - The company emphasizes the importance of independent directors and supervisory boards in safeguarding the interests of minority shareholders[103]. Environmental Management - The company has established a comprehensive environmental monitoring plan, with third-party testing confirming that all pollutant indicators meet discharge standards[90]. - The company has invested in waste treatment equipment to comply with environmental standards, but operational issues may still lead to penalties[64]. - The company has implemented an emergency response plan for environmental incidents, which has been filed with local environmental authorities[85]. - The company achieved a reduction of 53 tons in carbon dioxide equivalent emissions during the reporting period through various carbon reduction measures, including peak electricity usage management and solvent recovery[97]. - The company has received ISO14001 certification for its environmental management system, with re-certification planned for March 2024[96]. Risks and Challenges - There are no significant risks that materially affect the company's operations during the reporting period[5]. - The company faces risks related to industry policy changes, which could increase operational costs and impact performance if not adapted to timely[63]. - Environmental regulations are becoming stricter, potentially increasing the company's environmental management costs and affecting profitability[64]. - The company is exposed to risks from natural disasters, such as typhoons, which could disrupt normal operations[65]. - The company must renew key operational licenses periodically, and failure to do so could halt production and sales, impacting financial performance[63]. Shareholder and Capital Structure - The company repurchased 2,170,103 shares, accounting for 1.8911% of the total share capital, with a total repurchase amount of 54,992,179.00 RMB, reflecting a commitment to long-term value and employee incentives[51]. - The company’s major shareholders have committed to not interfere with the company's management activities and to comply with relevant regulations[106]. - The company has pledged to adhere to the latest regulations from the China Securities Regulatory Commission regarding compensation measures[106]. - The controlling shareholders have pledged not to sell their shares through secondary markets or bulk transactions for the next 12 months, reinforcing investor confidence[109]. - The company has a total of 9,554 common shareholders as of the end of the reporting period[122]. Compliance and Legal Matters - There are no significant lawsuits or arbitration matters reported during the reporting period, indicating a stable legal environment for the company[110]. - The company has not engaged in any major related party transactions during the reporting period, maintaining transparency in its financial dealings[111]. - There are no non-operational fund occupations by controlling shareholders or related parties, ensuring proper use of company funds[110]. - The company has not reported any violations or penalties against its directors, supervisors, or senior management, reflecting good governance practices[110]. - The company has not disclosed any major contracts or their execution status, suggesting a focus on operational efficiency[111].

浙江东亚药业股份有限公司 关于聘任董事会秘书的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈 述或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 | 证券代码：605177 | 证券简称：东亚药业 | 公告编号：2024-070 | | --- | --- | --- | | 债券代码：111015 | 债券简称：东亚转债 | | 周剑波先生具有良好的职业道德和个人品质，具备履行职责所必须的专业知 识和工作经验。周剑波先生已取得上海证券交易所颁发的科创板上市公司《董事 会秘书资格证明》，暂未完成上海证券交易所主板上市公司董事会秘书任前培训， 其承诺将参加最近一期上海证券交易所主板上市公司董事会秘书任职资格培训。 浙江东亚药业股份有限公司（以下简称"公司"）于 2024 年 8 月 29 日召开了 第三届董事会第二十八次会议，审议通过了《关于聘任公司董事会秘书的议案》， 现将有关情况公告如下： 截至本公告日，周剑波先生未持有公司股份，与公司控股股东、实际控制人 以及其他董事、监事、高级管理人员和持股 5%以上公司股东不存在关联关系, 亦不存在被中国证监会、证券交易所或其他有 ...

二、董事会会议审议情况 经各位董事认真审议，会议形成了如下决议： | 证券代码：605177 | 证券简称：东亚药业 | 公告编号：2024-069 | | --- | --- | --- | | 债券代码：111015 | 债券简称：东亚转债 | | 浙江东亚药业股份有限公司 第三届董事会第二十八次会议决议公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 一、董事会会议召开情况 浙江东亚药业股份有限公司（以下简称"公司"）第三届董事会第二十八次会议 于 2024 年 8 月 29 日（星期四）以现场结合通讯的方式召开。本次会议通知于 2024 年 8 月 19 日以邮件的方式发出。本次会议应出席董事 7 人，实际出席董事 7 人。 会议由公司董事长池正明先生主持，监事、高管列席会议。本次会议的召集、 召开符合《中华人民共和国公司法》等法律、法规和《公司章程》的有关规定。 （三）审议通过《关于 2024 年半年度募集资金存放与实际使用情况的专项报告 的议案》 （一）审议通过《关于聘任董事会秘书的议案》 本议案已经公司董事会 ...